NCT00779220TerminatedPhase 2
A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Chugai Pharmaceutical
- Enrollment
- 152
- Locations
- 7
- Primary Endpoint
- Percentage of patients with ACR20 response.
Study Overview
Brief Summary
This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in combination with methotrexate（MTX）in patients with active rheumatoid arthritis (RA). The data from this study will also be compared with those from a clinical study of ocrelizumab in patients with active RA that was conducted in the U.S.
Detailed Description
This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in combination with MTX in patients with active RA. The data from this study will also be compared with those from a clinical study of ocrelizumab in patients with active RA that was conducted in the U.S.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of RA for ≧6 months according to the revised 1987 ACR criteria for the classification of RA.
- •Adult patients, ≧20 years of age.
- •Receiving methotrexate at a dose of 6 to 8mg/week（oral）for ≧12 weeks, with a stable dose for the last 4 weeks before treatment.
- •Positive serum RF.
Exclusion Criteria
- •Rheumatic autoimmune disease other than RA, or Significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome).Patients with secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA are eligible.
- •Functional Class Ⅳ as defined by the ACR Classification of Functional Status in RA.
- •History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome).
- •Any surgical procedure (except for minor surgeries requiring local or no anaesthesia and without any complications or sequelae) within 12 weeks prior to or planned within 24 weeks after baseline.
Arms & Interventions
1
Placebo Comparator
Intervention: placebo (Drug)
1
Placebo Comparator
Intervention: methotrexate (Drug)
2
Experimental
Intervention: methotrexate (Drug)
2
Experimental
Intervention: ocrelizumabu 50mg (Drug)
3
Experimental
Intervention: methotrexate (Drug)
3
Experimental
Intervention: ocrelizumabu 200mg (Drug)
4:
Experimental
Intervention: methotrexate (Drug)
4:
Experimental
Intervention: ocrelizumab 500mg (Drug)
Outcomes
Primary Outcomes
Percentage of patients with ACR20 response.
Time Frame: week 24
Secondary Outcomes
- Percentage of patients with ACR20, 50, and 70 response, and the components of this outcome.(very 4 Weeks, from Week 4 to Week 24)
- EULAR response rate.(Every 4 Weeks, from Week 4 to Week 24)
- DAS 28, HAQ-DI score.(Every 4 Weeks, from Week 4 to Week 24)
- FACIT Fatigue Scale score(Weeks 4,12,and 24)
- Weeks 4,12,and 24(Length of study)
- Incidence of human anti-human(ocrelizumab) antibodies (HAHA)(Length of study)
- Pharmacokinetics and Pharmacodynamics of ocrelizumab.(Length of study)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Terminated
Phase 3
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)Rheumatoid ArthritisNCT00485589Genentech, Inc.613
Terminated
Phase 3
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)Rheumatoid ArthritisNCT00406419Genentech, Inc.1,015
Terminated
Phase 3
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate TherapyRheumatoid ArthritisNCT00673920Genentech, Inc.314
Terminated
Phase 3
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)Rheumatoid ArthritisNCT00476996Genentech, Inc.836
Active, not recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Relapsing-Remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT05123703Hoffmann-La Roche188